We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cannabis Compounds Show Promise for Chronic Pain Relief Without High

Cannabis leaves.
Credit: Matthew Brodeur / Unsplash.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Summary

Yale researchers found that cannabis-derived compounds CBD, CBG and CBN reduce pain signaling by inhibiting the Nav1.8 protein in sensory neurons. CBG showed the strongest effect. The findings suggest these cannabinoids could provide safer pain relief without addiction risks, offering a promising alternative to opioids for chronic pain management.

Key Takeaways

  • Non-Psychoactive Relief: CBD, CBG and CBN block pain signaling without causing a high.
  • Targeting Nav1.8: These cannabinoids inhibit a key protein involved in transmitting pain.
  • Potential Opioid Alternative: CBG showed the strongest effect, suggesting a safer option for chronic pain treatment.

  • Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers identify alternative compounds with therapeutic potential — chemicals found in cannabis that lack the mind-altering effects associated with the drug.


    The chemicals — cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN), which belong to a group of molecules known as cannabinoids — reduced the activity of a protein that is central to pain signaling in the peripheral nervous system, the study showed.


    The findings, published Jan. 21 in the Proceedings of the National Academy of Sciences, offer a promising new approach for safe and effective pain relief, said the researchers.

    Want more breaking news?

    Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

    Subscribe for FREE

    “These findings open new avenues for the development of cannabinoid-based therapies,” said Mohammad-Reza Ghovanloo, lead author of the study and an associate research scientist in the Department of Neurology at Yale School of Medicine. “Our results show that CBG in particular has the strongest potential to provide effective pain relief without the risks associated with traditional treatments.”


    Those risks include addiction, which is associated with opioids, one class of drugs prescribed for severe pain. The United States continues to be affected by the opioid epidemic — more than 80,000 people have died annually from opioid overdoses in recent years.


    Cannabinoids may also yield more effective pain management than other opioid alternatives, Ghovanloo added.


    The cannabinoids highlighted in the study interact with a protein found in the cell membrane of sensory neurons in the spine. The protein, called Nav1.8, enables repetitive firing of those neurons, which is a key process in transmitting pain signals. Blocking Nav1.8, and thereby muting its activity, has shown promise in reducing pain in recent clinical studies.


    In the new study, the researchers measured the electrical current in rodent sensory neurons and how the current changed when CBDCBG, and CBN were introduced. Each of the three cannabinoids reduced the cells’ electrical current amplitudes associated with Nav1.8. Of the three, CBG inhibited Nav1.8 action most strongly.


    The findings indicate that these three cannabinoids — and CBG in particular — can prevent sensory neurons in the body from sending pain signals to the brain. The researchers are optimistic that these compounds could provide a safer alternative for pain management and reduce reliance on opioids.


    “This research builds on the growing interest in the therapeutic potential of cannabinoids, highlighting their role in addressing chronic pain conditions such as neuropathic pain, arthritis, and inflammatory disorders,” said Dr. Stephen G. Waxman, senior author of the study and the Bridget M. Flaherty Professor of Neurology at Yale School of Medicine. “By focusing on Nav1.8 as a therapeutic target, the study paves the way for the development of innovative, cannabinoid-based pain treatments.”


    Reference: Ghovanloo MR, Tyagi S, Zhao P, Waxman SG. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. Proc Natl Acad Sci USA. 2025;122(4):e2416886122. doi: 10.1073/pnas.2416886122


    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.


    This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.